글루카곤 시장 : 제품 유형, 용도, 유통 채널별 - 세계 예측(2024-2032년)

Global Glucagon Market will exhibit over 5.9% CAGR between 2024 and 2032, catapulted by the thriving adoption of self-administration devices. These devices, designed for ease of use, empower patients to manage hypoglycemic episodes independently, enhancing convenience and compliance. The shift toward self-administration reduces the need for immediate medical assistance, which is particularly beneficial for diabetic patients who experience sudden drops in blood sugar levels.

In August 2023, Xeris Pharmaceuticals Inc. reported that 78% of commercially insured and Medicare beneficiaries had unrestricted access to Gvoke HypoPen, a glucagon injection for severe hypoglycemia treatment. This trend is encouraged by the development of intuitive and reliable delivery systems, which ensure accurate dosing and reduce the anxiety associated with emergency glucagon use. The demand for glucagon products will upsurge significantly.

The overall glucagon market is categorized based on product type, application, distribution channel, and region.

From 2024 to 2032, the inhalation segment will depict substantial CAGR growth due to its non-invasive and convenient delivery method, which is appealing to patients who are uncomfortable with injections. Inhalation glucagon offers rapid absorption and onset of action, making it an effective emergency treatment for hypoglycemia. Additionally, its ease of use ensures better adherence among patients, including children and the elderly, who struggle with traditional injection methods. This advancement in drug delivery technology enhances patient experience and accessibility, amplifying the increasing demand in the inhalation segment.

The diagnostic aid segment will possess a significant glucagon market share by 2032. The demand for glucagon in the diagnostic aid segment is increasing owing to its utility in various medical procedures such as gastrointestinal motility studies and imaging scans. Glucagon is used to relax the smooth muscles of the gastrointestinal tract, facilitating clearer imaging results and aiding in diagnostic accuracy. Its effectiveness in temporarily inhibiting insulin secretion also proves valuable in certain diagnostic tests. As medical procedures evolve and imaging technologies advance, the demand for glucagon as a diagnostic aid continues to grow, directed by its role in enhancing diagnostic capabilities and patient care outcomes.

From 2024 to 2032, North America glucagon market will demonstrate a healthy CAGR. Increasing urbanization and the adoption of a more sedentary lifestyle contribute to a higher prevalence of diabetes and related complications, necessitating effective management solutions such as glucagon. Improving healthcare infrastructure and rising disposable incomes are expanding access to diabetes care products. Government initiatives aimed at improving public health awareness and diabetes management also play a crucial role in stimulating market growth. These factors aid the growing demand for glucagon in the Asia Pacific.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
  • 3.2.2 Rising prevalence of diabetes
  • 3.2.3 Increasing research & development activities
  • 3.2.4 Growing demand for non-injectable emergency glycogen
  • 3.2.5 Advancements in pharmaceutical sector
  • 3.2.6 Industry pitfalls & challenges
  • 3.2.7 Lack of consumer awareness
  • 3.2.8 Stringent regulatory framework
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Company matrix analysis
• 4.5 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Injectable
• 5.3 Inhalation

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hypoglycemia
• 6.3 Diagnostic aid
• 6.4 Gastrointestinal disorders
• 6.5 Cardiogenic shock
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Amgen Inc.
• 9.2 Avalon Pharma Private Limited
• 9.3 Bachem Holding AG
• 9.4 Eli Lilly and Company
• 9.5 Fresenius SE & Co. KGaA
• 9.6 Fujifilm Holdings Corporation
• 9.7 Novo Nordisk A/S
• 9.8 Pfizer, Inc.
• 9.9 Svar Life Science
• 9.10 Taj Pharmaceuticals Ltd.
• 9.11 Xeris Biopharma Holdings, Inc.